Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sulfiting agents

Executive Summary

According to a draft proposal, FDA plans to require that a warning statement be included in the labeling of all Rx drugs for human use which contain sulfites that states: "Contains (insert the name of the sulfite, e.g., sodium metabisulfite), a sulfite that may cause serious allergic-type reactions (e.g., hives, itching, wheezing, anaphylaxis) in certain susceptible persons. Although the overall incidence of sulfite sensitivity in the general population is probably low, it is seen more frequently in asthmatics or in atopic nonasthmatic persons." The proposal has been signed by HHS Secty. Heckler and sent to the Office of Management and Budget.

You may also be interested in...



Coronavirus: Can Companies Achieve Vaccine Ambition?

Brilinta Boost For AZ In Stroke Study

Novo Awaits EMA’s Verdict On Oral Form Of Antidiabetic Blockbuster Semaglutide

Alnylam’s Givlaari for acute hepatic porphyria is also among the 14 new products that could get an EU approval recommendation this week.

UsernamePublicRestriction

Register

PS009197

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel